Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Escherichia coli
Study findings from National Institutes of Health broaden understanding of Escherichia coli
December 10th, 2008
According to recent research published in the journal Biotechnology and Bioengineering, "Plasmid DNA (pDNA) is an emerging experimental vaccine, Produced in E. coli, initially targeted for viral diseases. Unlike traditional protein vaccines whose average dose is micrograms, the average dose of pDNA is on the scale of milligrams." "Production yields are, therefore, important for the future development of this vaccine. The E. coli strains currently used for pDNA production, JM109 and DH5 alpha, are both suitable for production of stable pDNA due to the deletion of recA and endA, however, these two E. coli K strains are sensitive to growth conditions such as high...
Source: Vaccine Weekly (2008-12-10)
|
